“DCGI has made it mandatory for all manufacturers and importers who have obtain new drug permission to submit Periodic Safety Update Reports of new drug every six months for the first two year and for the subsequent two years it should be submitted annually”.
The Categorisation Problem Of all the challenges in India’s Cosmetic Import registration process, product categorisation is one of the most underestimated. Under the Cosmetics Rules, 2020, CDSCO..
For foreign Medical Device companies entering India, the authorized agent is not just a compliance checkpoint — it is a strategic regulatory role. The right appointment can support licensing procedu..
Why India Demands a Dedicated Biosimilar Strategy India is one of the fastest-growing Biosimilar markets in the world, driven by a large patient population, expanding government healthcare coverage un..
India
Global
Sales: +91 7672005050
Reception: +91-11-45214546
9 am to 6 pm (Monday to Friday)